ARCHIVES

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Advocacy: Jay Hedlund Resigns As NPCC President

May 14, 1999

In Brief: DCT Board Rejects Move to Count Individual P01 Projects Toward The NIH Total Of 5,000 Grants

June 24, 1983

Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients

December 28, 2012

FDA Advisors Debate Ban, Black Box And Status Quo of Power Morcellators

July 25, 2014

In Brief: NCAB Appointments: Boutwell Stay On; Brown, Elion, Strong, Korn Named; One Vacancy Remains

May 18, 1984

Centocor Withdraws Yondelis After FDA Calls for New Study

April 29, 2011